{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:07:00Z","timestamp":1786118820406,"version":"build-2736575974"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Because clinical data to confirm the safety and effectiveness of fosphenytoin, a prodrug of phenytoin, are insufficient, the length of administration of fosphenytoin is restricted. Nevertheless, some cases require fosphenytoin administration for more than a few days. The aim of this study was to retrospectively investigate the serum concentration of phenytoin in adult Japanese patients who received intravenous fosphenytoin therapy for more than 3 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patients injected with intravenous fosphenytoin for more than 3 days at Gifu University Hospital between January 2012 and September 2014 were enrolled. Individual pharmacokinetic parameters were predicted by Bayesian estimation using NONMEM software, and the maintenance dose of fosphenytoin required to maintain the therapeutic trough concentration (10\u201320 mcg\/mL) was calculated from the parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Among a total of 8 patients, the serum trough concentration of phenytoin decreased with each day after repeated injection of fosphenytoin. The incidence rate of significant convulsive seizures was increased time dependently (0% on day 1, 12.5% on day 2, 25% on day 3, and 66.7% on day 4 and after). Phenytoin clearance showed a time-dependent increase. The maintenance dose of fosphenytoin required to maintain the therapeutic trough concentration was simulated to be 779.8 \u00b1 316.8 mg\/d, a dose that was markedly higher than the actual maintenance dose (414.1 \u00b1 55.7 mg\/d).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Prolonged use of fosphenytoin, for such patients as those with autoimmune-mediated encephalopathy accompanied with reflux disease and\/or ileus, time dependently decreased the serum concentration of phenytoin and increased the risk of convulsion. Therefore, the maintenance dose should be increased to maintain the therapeutic serum concentration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000521","type":"journal-article","created":{"date-parts":[[2018,4,20]],"date-time":"2018-04-20T18:09:47Z","timestamp":1524247787000},"page":"507-511","source":"Crossref","is-referenced-by-count":3,"title":["Time-Dependent Decline in Serum Phenytoin Concentration With Heightened Convulsive Seizure Risk by Prolonged Administration of Fosphenytoin in Japanese: A Retrospective Study"],"prefix":"10.1097","volume":"40","author":[{"given":"Yuta","family":"Ohno","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Gifu University Hospital, Gifu;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Niwa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Gifu University Hospital, Gifu;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Hirai","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Genetics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Gifu University Hospital, Gifu;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuto","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Gifu University Hospital, Gifu;"},{"name":"Laboratory of Pharmacy Practice and Social Science, Gifu Pharmaceutical University, Gifu; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Neurology and Geriatrics, Gifu University Graduate School of Medicine, Gifu, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacy Practice and Social Science, Gifu Pharmaceutical University, Gifu; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Gifu University Hospital, Gifu;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Itoh","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Gifu University Hospital, Gifu;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.0013-9580.2005.66104.x","article-title":"Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE)","volume":"46","author":"Fisher","year":"2005","journal-title":"Epilepsia."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1474-4422(15)00042-3","article-title":"Status epilepticus in adults","volume":"14","author":"Betjemann","year":"2015","journal-title":"Lancet Neurol."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s00415-017-8391-5","article-title":"Phenytoin: 80 years young, from epilepsy to breast cancer, a remarkable molecule with multiple modes of action","volume":"264","author":"Keppel Hesselink","year":"2017","journal-title":"J Neurol."},{"key":"R6-20230814","first-page":"489","article-title":"Population pharmacokinetics of phenytoin after intravenous administration of fosphenytoin sodium in pediatric patients, adult patients, and healthy volunteers","volume":"69","author":"Tanaka","year":"2013","journal-title":"Eur J Clin Pharmacol."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/j.1552-4604.1988.tb03124.x","article-title":"Safety, tolerance and pharmacokinetics of intravenous doses of the phosphate ester of 3-hydroxymethyl-5,5-diphenylhydantoin: a new prodrug of phenytoin","volume":"28","author":"Gerber","year":"1988","journal-title":"J Clin Pharmacol."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/clinchem\/44.3.696","article-title":"Cross-reactivity of fosphenytoin in four phenytoin immunoassays","volume":"44","author":"Datta","year":"1998","journal-title":"Clin Chem."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1528-1157.1999.tb00778.x","article-title":"Pharmacokinetics of fosphenytoin in patients with hepatic or renal disease","volume":"40","author":"Aweeka","year":"1999","journal-title":"Epilepsia."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1124\/dmd.32.3.348","article-title":"Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers","volume":"32","author":"Faucette","year":"2004","journal-title":"Drug Metab Dispos."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/0006-291X(91)91680-B","article-title":"Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9","volume":"175","author":"Veronese","year":"1991","journal-title":"Biochem Biophys Res Commun."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/S0090-9556(25)08481-8","article-title":"Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite","volume":"24","author":"Bajpai","year":"1996","journal-title":"Drug Metab Dispos."},{"key":"R13-20230814","first-page":"455","article-title":"Explanation of dose-dependent decline of diphenylhydantoin plasma levels by fitting to the integrated form of the Michaelis-Menten equation","volume":"3","author":"Gerber","year":"1972","journal-title":"Res Commun Chem Pathol Pharmacol."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/BF01063122","article-title":"Nonlinear assessment of phenytoin bioavailability","volume":"4","author":"Jusko","year":"1976","journal-title":"J Pharmacokinet Biopharm."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00007691-201808000-00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:50:12Z","timestamp":1786035012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007691-201808000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000521","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}